Donna Reece

26PUBLICATIONS
64CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Feb 24, 2026
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Carlyn Rose Tan, Saad Z Usmani, Andriy Derkach

|Oct 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection.

Alissa Visram, Dirk Larson, Aaron Norman

|Sep 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.

Arleigh McCurdy, Donna Reece, Martha L Louzada

|Jan 04, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.

Suzanne Trudel, Arleigh McCurdy, Martha L Louzada

|Dec 08, 2023
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.

A Visram, A De La Torre, D White

|Aug 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

Richard LeBlanc, Hira Mian, Donna Reece

Pageof 5

Frequent Collaborators

10 joint publications

Shaji Kumar

10 joint publications

Angela Dispenzieri

10 joint publications

Hira Mian

8 joint publications

Eli Muchtar